Somatostatin is released in response to cholecystokinin by activation of type A CCK receptors

Kevin C K Lloyd, V. Maxwell, C. N. Chuang, H. C. Wong, A. H. Soll, J. H. Walsh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Cholecystokinin is a principal mediator of intestinal fat-induced inhibition of gastric acid secretion, indicating that it is an important physiological enterogastrone. Cholecystokinin has been shown to inhibit acid secretion by activation of type A CCK receptors and through a mechanism involving somatostatin. In the present study, we investigated the possibility that these two mechanisms are directly related such that activation of type A CCK receptors by CCK causes the release of somatostatin. We tested this hypothesis in vivo in a study of CCK-stimulated release of somatostatin in dogs and in vitro in a study of CCK-stimulated release of somatostatin from an enriched culture of canine fundic D cells. In dogs, IV infusion of CCK (50 pmol/kg/h, IV) significantly increased circulating somatostatin concentrations above basal. Further, systemic administration of somatostatin MAb F(ab)1 fragments of a somatostatin monoclonal antibody prevented most of CCK-induced inhibition of meal-stimulated acid secretion. In canine fundic D cells in culture, CCK-stimulated somatostatin release was blocked in a dose-dependent fashion by application of a type A CCK receptor antagonist. This study indicates that CCK activates type A CCK receptors to release somatostatin from canine fundic mucosal D cells, and accounts for somatostatin-dependent CCK-induced inhibition of acid secretion.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalPeptides
Volume15
Issue number2
DOIs
StatePublished - 1994

Fingerprint

Cholecystokinin A Receptor
Cholecystokinin
Somatostatin
Chemical activation
Somatostatin-Secreting Cells
Canidae
Acids
Dogs
Gastric Acid
Meals
Cell Culture Techniques
Fats
Monoclonal Antibodies

Keywords

  • Cholecystokinin (CCK)
  • D cells
  • Dog
  • Enterogastrone
  • Gastric acid secretion
  • Radioimmunoassay
  • Somatostatin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Somatostatin is released in response to cholecystokinin by activation of type A CCK receptors. / Lloyd, Kevin C K; Maxwell, V.; Chuang, C. N.; Wong, H. C.; Soll, A. H.; Walsh, J. H.

In: Peptides, Vol. 15, No. 2, 1994, p. 223-227.

Research output: Contribution to journalArticle

Lloyd, Kevin C K ; Maxwell, V. ; Chuang, C. N. ; Wong, H. C. ; Soll, A. H. ; Walsh, J. H. / Somatostatin is released in response to cholecystokinin by activation of type A CCK receptors. In: Peptides. 1994 ; Vol. 15, No. 2. pp. 223-227.
@article{8e473a93662343159b842b30359ebb8e,
title = "Somatostatin is released in response to cholecystokinin by activation of type A CCK receptors",
abstract = "Cholecystokinin is a principal mediator of intestinal fat-induced inhibition of gastric acid secretion, indicating that it is an important physiological enterogastrone. Cholecystokinin has been shown to inhibit acid secretion by activation of type A CCK receptors and through a mechanism involving somatostatin. In the present study, we investigated the possibility that these two mechanisms are directly related such that activation of type A CCK receptors by CCK causes the release of somatostatin. We tested this hypothesis in vivo in a study of CCK-stimulated release of somatostatin in dogs and in vitro in a study of CCK-stimulated release of somatostatin from an enriched culture of canine fundic D cells. In dogs, IV infusion of CCK (50 pmol/kg/h, IV) significantly increased circulating somatostatin concentrations above basal. Further, systemic administration of somatostatin MAb F(ab)1 fragments of a somatostatin monoclonal antibody prevented most of CCK-induced inhibition of meal-stimulated acid secretion. In canine fundic D cells in culture, CCK-stimulated somatostatin release was blocked in a dose-dependent fashion by application of a type A CCK receptor antagonist. This study indicates that CCK activates type A CCK receptors to release somatostatin from canine fundic mucosal D cells, and accounts for somatostatin-dependent CCK-induced inhibition of acid secretion.",
keywords = "Cholecystokinin (CCK), D cells, Dog, Enterogastrone, Gastric acid secretion, Radioimmunoassay, Somatostatin",
author = "Lloyd, {Kevin C K} and V. Maxwell and Chuang, {C. N.} and Wong, {H. C.} and Soll, {A. H.} and Walsh, {J. H.}",
year = "1994",
doi = "10.1016/0196-9781(94)90006-X",
language = "English (US)",
volume = "15",
pages = "223--227",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Somatostatin is released in response to cholecystokinin by activation of type A CCK receptors

AU - Lloyd, Kevin C K

AU - Maxwell, V.

AU - Chuang, C. N.

AU - Wong, H. C.

AU - Soll, A. H.

AU - Walsh, J. H.

PY - 1994

Y1 - 1994

N2 - Cholecystokinin is a principal mediator of intestinal fat-induced inhibition of gastric acid secretion, indicating that it is an important physiological enterogastrone. Cholecystokinin has been shown to inhibit acid secretion by activation of type A CCK receptors and through a mechanism involving somatostatin. In the present study, we investigated the possibility that these two mechanisms are directly related such that activation of type A CCK receptors by CCK causes the release of somatostatin. We tested this hypothesis in vivo in a study of CCK-stimulated release of somatostatin in dogs and in vitro in a study of CCK-stimulated release of somatostatin from an enriched culture of canine fundic D cells. In dogs, IV infusion of CCK (50 pmol/kg/h, IV) significantly increased circulating somatostatin concentrations above basal. Further, systemic administration of somatostatin MAb F(ab)1 fragments of a somatostatin monoclonal antibody prevented most of CCK-induced inhibition of meal-stimulated acid secretion. In canine fundic D cells in culture, CCK-stimulated somatostatin release was blocked in a dose-dependent fashion by application of a type A CCK receptor antagonist. This study indicates that CCK activates type A CCK receptors to release somatostatin from canine fundic mucosal D cells, and accounts for somatostatin-dependent CCK-induced inhibition of acid secretion.

AB - Cholecystokinin is a principal mediator of intestinal fat-induced inhibition of gastric acid secretion, indicating that it is an important physiological enterogastrone. Cholecystokinin has been shown to inhibit acid secretion by activation of type A CCK receptors and through a mechanism involving somatostatin. In the present study, we investigated the possibility that these two mechanisms are directly related such that activation of type A CCK receptors by CCK causes the release of somatostatin. We tested this hypothesis in vivo in a study of CCK-stimulated release of somatostatin in dogs and in vitro in a study of CCK-stimulated release of somatostatin from an enriched culture of canine fundic D cells. In dogs, IV infusion of CCK (50 pmol/kg/h, IV) significantly increased circulating somatostatin concentrations above basal. Further, systemic administration of somatostatin MAb F(ab)1 fragments of a somatostatin monoclonal antibody prevented most of CCK-induced inhibition of meal-stimulated acid secretion. In canine fundic D cells in culture, CCK-stimulated somatostatin release was blocked in a dose-dependent fashion by application of a type A CCK receptor antagonist. This study indicates that CCK activates type A CCK receptors to release somatostatin from canine fundic mucosal D cells, and accounts for somatostatin-dependent CCK-induced inhibition of acid secretion.

KW - Cholecystokinin (CCK)

KW - D cells

KW - Dog

KW - Enterogastrone

KW - Gastric acid secretion

KW - Radioimmunoassay

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0028178018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028178018&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(94)90006-X

DO - 10.1016/0196-9781(94)90006-X

M3 - Article

C2 - 7911992

AN - SCOPUS:0028178018

VL - 15

SP - 223

EP - 227

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 2

ER -